Sanofi SA


  • The worst-ever Ebola outbreak, which has already killed at least 2,296 people in West Africa, has triggered a scramble to develop the first drug or vaccine for a deadly disease that was discovered nearly 40 years ago in the forests of central Africa.

  • Long-awaited diet pill gets U.S. approval Wednesday, 10 Sep 2014 | 9:00 PM ET

    Sept 10- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

  • Sept 10- Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA's blockbuster insulin, Lantus. The therapy received a positive recommendation from the European Medicine Agency in June.

  • Sept 5- Keryx Biopharmaceuticals Inc won U.S. approval for its drug to lower phosphate levels in patients with chronic kidney disease, but the approval included an unexpected safety warning on the label. However, the FDA- mandated label does not include the benefits of the drug in treating anemia.

  • Keryx Biopharma gets U.S. approval for kidney drug Friday, 5 Sep 2014 | 11:28 AM ET

    Sept 5- Keryx Biopharmaceuticals Inc won the U.S. Food and Drug Administration approval for its drug to lower phosphate levels in patients with chronic kidney disease who are already on dialysis. It affects more than 20 million adults in the United States, according to the U.S. Centers for Disease Control and Prevention.

  • *10 cents move in euro: 1 bln euro swing in Airbus's op profits. *Airbus, Sanofi, Luxottica seen among big winners.

  • PARIS, Sept 3- French drugmaker Sanofi, developing the first vaccine against dengue fever, said its product reduced disease cases by 60.8 percent in a large final clinical trial. Sanofi has invested more than 1.3 billion euros in the project, undertaking two decades of research on the world's fastest-growing tropical disease.

  • Cramer sees 'breakout' for this stock Tuesday, 2 Sep 2014 | 10:29 AM ET
    Jim Cramer

    That clinical trials for a cholesterol-lowering drug exceed expectations will boost the developer's stock, says CNBC's Jim Cramer.

  • Early movers: FDO, DG, DLTR, SNY, AAPL, GPS & more Tuesday, 2 Sep 2014 | 7:35 AM ET
    A trader works on the floor of the New York Stock Exchange in New York.

    Some of the names on the move ahead of the open.

  • *Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.

  • *Sanofi, Regeneron vying with drugs from Amgen and Pfizer. BARCELONA, Aug 31- An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.

  • WASHINGTON, Aug 27- International Business Machines Corp on Wednesday launched a computer system that can quickly identify patterns in massive amounts of data, an ability that IBM said should hasten breakthroughs in science and medical research. IBM will make the service available through the cloud.

  • *Drug has orphan drug status in US, EU and Japan. Aug 20- Amicus Therapeutics Inc moved a step closer to bringing its first drug to the market after trial results paved the way for its lead drug to become the first oral treatment for patients with a disorder that causes an abnormal build-up of fat.

  • Aug 20- Amicus Therapeutics Inc said its experimental drug was as effective as enzyme replacement therapies after 18 months in patients with Fabry disease, an inherited disorder that leads to the abnormal build-up of fat. The company's stock rose 38 percent in premarket trading on Wednesday after the results of the second late-stage trial were released.

  • Early movers: HD, BHP, BAC, URBN, RDEN, LLY & more Tuesday, 19 Aug 2014 | 7:56 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • NORWICH, England, Aug 17- Pampering leafcutter ants with fragrant rose petals and fresh oranges may seem an unlikely way to rescue modern medicine, but scientists at a lab in eastern England think it's well worth trying.

  • NEW YORK, Aug 13- Biotechnology company InterMune Inc is working with financial advisers to evaluate strategic options as it braces for potential takeover interest from larger drugmakers, people familiar with the matter said.

  • NEW YORK, Aug 11- U.S. stocks rose broadly on Monday, extending Friday's sharp rally as recent uncertainty pertaining to Ukraine and the Middle East appeared to ease, while Priceline rallied on its results.

  • BUSINESS-NEWS-SCHEDULE AT 1430 GMT / 10.30 AM ET Monday, 11 Aug 2014 | 11:31 AM ET

    NEW YORK- Global stocks bounce after recent sell-offs and core government debt prices fall as markets see receding risks of direct conflict between Russia and Ukraine while Middle East tensions diminish.

  • *MannKind signs agreement with Sanofi, shares jump. NEW YORK, Aug 11- U.S. stocks rose on Monday, extending Friday's sharp rally as concerns eased over both Federal Reserve monetary policy and the tense situation between Russia and Ukraine.